Sequoia-backed Whole Biome wants to heal your gut with medical-grade probiotics

Whole Biome has pulled in $35 million in Series B financing from a list of investing titans, including Sequoia, Khosla, True Ventures, the Mayo Foundation and AME Ventues — just to name a few. The goal? to heal what ails you using microscopic bugs.

Medical science has caught on in the last few years about the importance of gut health using these bugs (also known as probiotics). Now startups are pitching in using venture money to come up with new and novel ideas.

“We’re at a unique point in time as the field of microbiome biology converges with enabling cutting-edge technologies and bioinformatics that will open up a whole new world of innovative health products,” said Colleen Cutcliffe, Whole Biome’s co-founder and chief executive officer.

Cutliffe, who hails from DNA sequencing company Pacific Biosciences, along with her partners Jim Bullard and John Eid, built a platform able to compute information from varying populations and compare microbiome sequencing to get a clear picture of what’s missing in a patient’s flora for overall health.

The next step is to use the raised funds to launch a product for the management of Type 2 Diabetes.

Many of the prescription diabetes medications out on the market today can come with a load of side effects like upset stomach, dizziness, rashes or inability to consume alcohol. However, Whole Biome says their product will not have any side effects.

Slated for release in early 2020, the startup has conducted double-blinded, placebo-controlled, randomized clinical trials for a product, which releases special probiotics into your gut with the goal of reducing glucose spikes.

“Whole Biome is creating novel, disease-targeting microbiome interventions that have the potential to improve the course of many of the significant health issues facing people today,” said Sequoia partner Roelof Botha. “They have built an integrated approach and a multi-disciplinary team across research, development and commercialization to unlock complex microbiome biology and create products with both clinical efficacy and unparalleled safety.”

To date, Whole Biome has now raised $57 million in funding.